MITOTOX

Drug

D1429 | itraconazole

Properties

Molecular Formula	C35H38Cl2N8O4
Molecular Weight	705.6
Structure
State	solid
Clearance	* 381 +/- 95 mL/minute [IV administration]
Volume of distribution	* 796 ± 185 L
Route of elimination	Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.
Protein binding	0.998
Half life	21 hours
Absorption	The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.
Description	antifungal

Therapeutic Classification Source: DrugBank

J

J02AC02 Itraconazole

[J02AC] Triazole derivatives

[J02A] ANTIMYCOTICS FOR SYSTEMIC USE

[J02] ANTIMYCOTICS FOR SYSTEMIC USE

[J] Antiinfectives for systemic use

Mitochondrial Toxicity Evaulation

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
LIPID PEROXIDATION	4mg/ml		Aspergillus fumigatus		lipid peroxidation using the thiobarbituric acid assay	induce		304
LIPID PEROXIDATION	4mg/ml		Aspergillus fumigatus		mitochondrion-specific lipid peroxidation probe MitoPerOx	induce		304
ROS PRODUCTION	4mg/ml		Aspergillus fumigatus		oxidant-sensing fluorescent probe 2′,7′-dichlorofluorescin diacetate t	induce		304

Indications Source: SIDER

External IDs

DrugBank	DB01167
CAS Number	84625-61-6
PubChem Compound	55283

References